IO Biotech Exceeds Q2 2024 EPS Expectations
IO Biotech's Q2 2024 EPS beats estimates, reporting -31 cents vs. expected -35 cents, despite no revenue.
- Latest
- Trending
IO Biotech's Q2 2024 EPS beats estimates, reporting -31 cents vs. expected -35 cents, despite no revenue.
Google introduces Pixel phones with A.I. features to compete in the smartphone market, targeting Apple's iPhone dominance.
CryptoQuant CEO highlights Bitcoin's bullish on-chain indicators, suggesting a return to a bull market phase.
Google found guilty of monopoly practices. What does this mean for Alphabet's stock and future investment strategies?
S&P 500 fluctuates amid economic data anticipation, inflation and sales metrics in focus.
Ripple begins beta testing of its new stablecoin, Ripple USD, on XRP Ledger and Ethereum, awaiting regulatory approval.
JPMorgan requests to end NY suit against VTB citing coercion. Legal and financial stakes remain high amid sanctions.
Bitcoin nears $60K with a 6.4% jump, yet analysts warn of potential market volatility ahead.
Ripple's legal victory against the SEC could reshape cryptocurrency regulations and boost investor confidence.
SEC lawsuit against biotech firm for $9M misappropriation proceeds, as judge rules investors' interests prioritized over asset freeze appeal.
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.